Breaking Down SG&A Expenses: Novartis AG vs Catalent, Inc.

A Comparative Analysis of SG&A Expenses: Novartis AG vs Catalent, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Catalent, Inc. from 2014 to 2023. Over this period, Novartis AG consistently reported higher SG&A expenses, averaging around $14.5 billion annually, while Catalent, Inc. averaged approximately $571 million. Notably, Catalent's SG&A expenses surged by nearly 180% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Novartis AG's expenses showed a more stable trend, with a slight decline in 2023. This data highlights the contrasting financial strategies of these two pharmaceutical giants, with Catalent focusing on expansion and Novartis maintaining a steady course. Missing data for Novartis in 2024 suggests a potential shift or reporting delay, warranting further investigation.